非布司他片联合依托考昔治疗痛风性关节炎的效果及对血清炎症因子的影响

Abstract
Figure/Table
References (22)
Related Citation (5)

Download: PDF (432 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To observe the clinical effect of Febuxostat combined with Etoricoxib in the treatment of patients with gout arthritis and its effect on serum inflammatory factors. Methods Seventy-six patients with gout arthritis from October 2015 to October 2016 in the First Affiliated Hospital of Kunming Medical University were selected and randomly divided into control group and observation group by the odd even method, with 38 cases in each group. Patients in the control group were treated with Etoricoxib, 120 mg/time, once per day, for 1 week in a row. The observation group was treated with a combination of Febuxostat on the basis of the control group, 40 mg/time, once per day, for 1 week in a row. The clinical efficacy, pain relief and uric acid (UA), interleukin 1 (IL-1β), tumor necrosis factor (TNF-α), erythrocyte sedimentation rate (ESR), c-reactive protein (CRP) level of the two groups were observed and the adverse reaction were compared. Results The total effective rate of observation group was higher than control group, the difference was statistically significant (P ＜ 0.05). After treatment, the visual simulation score (VAS score) of the two groups was significantly reduced, and the VAS score in the observation group was lower than that in the control group, the difference was statistically significant (P ＜ 0.05). After treatment, the level of UA, IL-1β, TNF-α, ESR and CRP level in two groups were significantly lower than before treatment, and the levels of each factor in the observation group were better than those in the control group, the differences were statistically significant (P ＜ 0.05). There was no statistically significant of adverse reaction rates between the two groups (P ＞ 0.05). Conclusion The efficacy of Febuxostat combined with Etoricoxib in the treatment of gout arthritis has significantly efficiency, it is superior to use Etoricoxib singly. The clinical symptoms and serum inflammatory factors were significantly improved, and the safety is good, which is worthy of clinical promotion.

Key words： Febuxostat Etoricoxib Gout arthritis Inflammatory cytokines

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LAI Aiyun XU Jian TAO Li

Cite this article:

LAI Aiyun XU Jian TAO Li. The effect of Febuxostat combined with Etoricoxib in the treatment of patients with gout arthritis and its effect on serum inflammatory factors[J]. 中国医药导报, 2018, 15(9): 101-104.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2018/V15/I9/101

[1] Tausche AK，Aringer M. Gouty arthritis [J]. Z Rheumatol，2016，75（9）：885-898.
[2] 钟晓武，姚承佼，青玉凤，等.痛风性关节炎患者中长链非编码RNA的表达谱研究[J].中华风湿病学杂志，2017， 21（2）：74-78.
[3] 陈光亮，周媛凤，张颖.治疗痛风和高尿酸血症药物研究进展[J].中国临床药理学与治疗学，2017，22（1）：104-109.
[4] 匡丽.依托考昔治疗急性痛风的疗效观察[J].中国保健营养，2015，25（15）：247-248.
[5] 陈灏珠.实用内科学[M].12版.北京：人民卫生出版社，2005.
[6] 张乃峥.临床风湿病学[M].上海：上海科学技术出版社，1999，367-371.
[7] 武东，刘湘源.痛风的治疗进展[J].临床荟萃，2015，33（12）：1344-1346.
[8] 李朝霞，戴冽，莫颖倩，等.急性痛风性关节炎的疾病负荷及诊疗状况[J].广东医学，2016，37（19）：2953-2956.
[9] Terkeltaub RA，Schumacher HR，Carter JD，et al. Rilonacept in the treatment of acute gouty arthritis：a randomized，controlled clinical trial using indomethacin as the active comparator [J]. Arthritis Res Ther，2013，15（1）：R25-R32.
[10] Croom KF，Siddiqui MAA. Etoricoxib [J]. Drugs，2009，69（11）：1513-1532.
[11] 徐玲玲，李琳娜，薛耀明.依托考昔治疗急性重度痛风性关节炎的疗效及影响因素[J].医学研究杂志，2015， 21（2）：96-97.
[12] 江苏万邦生化医药股份有限公司.治疗痛风新药--非布司他片[J].上海医药，2015，26（11）：38.
[13] Pascual E，Sivera F，Yasothan U，et al. Febuxostat [J]. Nat Rev Drug Discov，2009，8（3）：191-197.
[14] 王丽坚，赵卫佐，朱小春.依托考昔对痛风性关节炎患者IL-1β、TNF-α的影响[J].中国生化药物杂志，2016， 36（12）：69-71.
[15] 陈春毅.依托考昔和美洛昔康在治疗膝骨关节炎中的可行性对比[J].中国医药科学，2015，（11）：77-79.
[16] 张徐明，姬森国，刘群，等.非布司他对急性痛风性关节炎患者氧化应激的影响[J].上海医药，2015，43（21）：28-31.
[17] 罗来敏.非布司他片治疗痛风伴高尿酸血症的临床研究及其对炎性因子IL-1β和NALP3水平的影响[D].南昌：南昌大学，2016.
[18] 丁焕发，王尚云，徐晓辰，等.急性痛风性关节炎患者治疗前后外周血单核细胞NLRP3炎性体mRNA表达及血清IL-1β水平的研究[J].中国医学创新，2016，13（20）：5-8
[19] Araújo F，Cordeiro I，Ramiro S，et al. Outcomes assessed in trials of gout and accordance with OMERACT-proposed domains：a systematic literature review [J]. Rheum?鄄atology，2015，54（6）：981-988.
[20] 隋磊，杨蕊菲，杜健，等.非布司他联合手术治疗痛风结节的疗效观察[J].中国现代医学杂志，2015，25（29）：73-77.
[21] Love BL，Robert B，Angie V，et al. Urate-lowering therapy for gout：focus on febuxostat [J]. Pharmacotherapy，2010， 30（6）：594-599.
[22] Xu L，Liu S，Guan M，et al. Comparison of Prednisolone，Etoricoxib，and Indomethacin in Treatment of Acute Gouty Arthritis：An Open-Label，Randomized，Controlled Trial [J]. Med Sci Monit，2016，22：810-817.